LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Relation today announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases. Under the terms of the agreement, Relation will receive 55 million, comprising an upfront payment, equity investment and additional R&D funding. In addition, Relation is eligible to receive preclinical, development, regulatory, and commercial sales milestones of up to 1.7 billion, along with tiered royalties on net sales of pro ...